Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Trilipix Clear all
Completed Phase 2 Interventional Results available

Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate

NCT01426438
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Niacin, Aspirin, Fenofibrate
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 5, 2026, 3:55 AM EDT
Completed Phase 2 Interventional

The Effect of Fish Oil Plus Fenofibrate on Triglyceride Levels in People Taking Highly Active Antiretroviral Therapy (HAART)

NCT00076518
View directory record Official record
Conditions
HIV Infections, Hypertriglyceridemia
Interventions
Fenofibrate, Fish Oil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
5
States / cities
San Francisco, California • Atlanta, Georgia • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 5, 2026, 3:55 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

NCT02023879
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 5, 2026, 3:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Fenofibrate 160mg Tablets Under Fed Conditions

NCT00775359
View directory record Official record
Conditions
Healthy
Interventions
Fenofibrate 160 mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 19, 2008 · Synced Sep 5, 2026, 3:55 AM EDT
Completed No phase listed Observational Results available

Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate

NCT05080192
View directory record Official record
Conditions
Covid19
Interventions
Fenofibrate, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Sep 5, 2026, 3:55 AM EDT
Completed Phase 2 Interventional

Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels

NCT00813527
View directory record Official record
Conditions
Hyperlipidemias
Interventions
Lapaquistat acetate and fenofibrate, Fenofibrate
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
32
States / cities
Huntsville, Alabama • Sierra Vista, Arizona • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Sep 5, 2026, 3:55 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.

NCT00300430
View directory record Official record
Conditions
Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia
Interventions
ABT-335 and rosuvastatin calcium, ABT-335 and atorvastatin calcium, ABT-335 and simvastatin
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
1,911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2009 · Synced Sep 5, 2026, 3:55 AM EDT
Recruiting Phase 2 Interventional

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

NCT01356290
View directory record Official record
Conditions
Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent, Rare CNS Tumor Recurrent
Interventions
Bevacizumab, Thalidomide, Celecoxib, Fenofibric acid, Etoposide, Cyclophosphamide, Etoposide phosphate, Cytarabine, Temozolomide (TMZ), Irinotecan
Drug
Lead sponsor
Medical University of Vienna
Other
Eligibility
Up to 19 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 5, 2026, 3:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Between ABT-335, Rosuvastatin and Warfarin

NCT00487136
View directory record Official record
Conditions
Healthy
Interventions
Warfarin, warfarin plus ABT-335 plus rosuvastatin 5 mg, warfarin plus ABT-335 plus rosuvastatin 20 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Sep 5, 2026, 3:55 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study of Trilipix Effects on Lipids and Arteries

NCT01025492
View directory record Official record
Conditions
Dyslipidemia
Interventions
Trilipix, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
30 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Sep 5, 2026, 3:55 AM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)

NCT03230916
View directory record Official record
Conditions
Suspected or Documented Gram-negative Bacterial Infection
Interventions
IMI/REL FDC
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 17 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Sep 5, 2026, 3:55 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function

NCT03001817
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
K-877, Fenofibrate, Placebo (for K-877), Placebo (for Fenofibrate)
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
110
States / cities
Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 94 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Sep 5, 2026, 3:55 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

NCT03011450
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
K-877, Fenofibrate, Placebo (for K-877)
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
129
States / cities
Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Sep 5, 2026, 3:55 AM EDT
Terminated Not applicable Interventional Results available

Effect of a Fibrate and a Statin on Endothelial Dysfunction

NCT00491400
View directory record Official record
Conditions
Diabetes Mellitus, Metabolic Syndrome
Interventions
Fenofibrate, Atorvastatin
Drug
Lead sponsor
Boston University
Other
Eligibility
30 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Sep 5, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study

NCT00400231
View directory record Official record
Conditions
Metabolic Syndrome x
Interventions
Study drugs: Metformin and fenofibrate, Study Drug: Metformin, Study Drug: fenofibrate, Metformin and Fenofibrate placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 5, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Results available

Use of Fenofibrate for Primary Biliary Cirrhosis

NCT00575042
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Gainesville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Sep 5, 2026, 3:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fenofibrate and Pharmacogenetic Impact in Dyslipidemia

NCT00613613
View directory record Official record
Conditions
Dyslipidemia
Interventions
fenofibrate
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 5, 2026, 3:55 AM EDT
Completed Phase 4 Interventional Results available

Fenofibrate in Type 2 Diabetes

NCT03829514
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Fenofibrate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Sep 5, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Results available

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

NCT00504829
View directory record Official record
Conditions
Dyslipidemia
Interventions
LCP-AtorFen, atorvastatin, fenofibrate
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 5, 2026, 3:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz

NCT01472380
View directory record Official record
Conditions
Healthy
Interventions
efavirenz, fenofibric acid 105 mg
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 5, 2026, 3:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis

NCT00422396
View directory record Official record
Conditions
Hypertriglyceridemia With the Metabolic Syndrome
Interventions
Fenofibrate (drug)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 5, 2026, 3:55 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

NCT03510884
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
8 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 5, 2026, 3:55 AM EDT
Completed Not applicable Interventional Results available

Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia

NCT00246376
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, HIV Infections, Hyperlipidemia, Hypertriglyceridemia, Insulin Resistance, Atherosclerosis
Interventions
Diet, Exercise, Niacin, Fenofibrate, Placebos
Behavioral · Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Sep 5, 2026, 3:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Predictors of Response to Fenofibrate

NCT01023750
View directory record Official record
Conditions
Hypertriglyceridemia, Insulin Resistance
Interventions
Fenofibrate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Sep 5, 2026, 3:55 AM EDT